Background {#Sec1}
==========

Asthma is the most common chronic condition among children with an estimated lifetime prevalence on 12% in Danish 5-year olds \[[@CR1]\]. It is commonly seen in a triad with atopic dermatitis and allergic rhinitis. The lifetime prevalence \[[@CR1]\] of atopic dermatitis at age 5 years in Danish children is 13%, and of rhinoconjunctivitis it is 7%. Asthma is characterized by recurrent airway obstruction and bronchial hyper-responsiveness \[[@CR2]\]. In many asthmatic children, wheezing and respiratory symptoms can be traced back to early childhood \[[@CR3]\]. The diagnosis in young children is symptom based, as they cannot collaborate in spirometry \[[@CR2]\]. However, asthma symptoms resemble symptoms of common infections like bronchitis.

Phthalates are synthetic chemical compounds used as plasticizers in consumer products. They form weak chemical bonds and are easily leached into the surrounding environment, and they can cross the placenta and affect the fetus \[[@CR4]\]. Phthalates have short biological half-lives from hours to a few days, but because exposure is ubiquitous, exposure levels may be relatively constant \[[@CR5], [@CR6]\]. We identified 14 prospective cohort studies \[[@CR5], [@CR7]--[@CR19]\] examining the association between prenatal phthalate exposure and asthma or allergy. Findings are inconsistent probably because different metabolites have been measured and the age of the children varied. Three studies \[[@CR9], [@CR11], [@CR16]\] measured metabolites of diisononyl phthalate (DiNP) and only one \[[@CR13]\] studied rhinitis.

To our knowledge, no Scandinavian prospective cohort studies have examined the association between in utero phthalate exposure and development of asthma and allergy, and we therefore used data from a prospective Danish birth cohort to examine the association between maternal urinary phthalate metabolite concentrations in third trimester and development of asthma, eczema and rhinitis in 552 offspring aged 5 years.

Materials and methods {#Sec2}
=====================

Study settings and participants {#Sec3}
-------------------------------

From 2010 to 2012 all newly pregnant women residing in Odense were invited to participate in the Odense Child Cohort (OCC) at Odense University Hospital between gestational age (GA) 10--16 weeks (earlier described in detail \[[@CR20]\]). Information on maternal pre-pregnancy Body Mass Index (BMI), maternal educational level and maternal smoking during pregnancy was obtained through questionnaires during pregnancy. Data on birth characteristics, maternal age, parity at inclusion and GA was obtained from hospital records. Preterm was defined as born before GA 37 weeks. Information on breastfeeding, smoking, pets and family history of asthma and allergy was obtained from questionnaires during the first 5 life years.

Phthalate metabolite measurements {#Sec4}
---------------------------------

At approximately GA 28 weeks 870 pregnant women delivered a fasting spot urine sample for analysis of total content (free and conjugated) of 12 phthalate metabolites, of which some were summed (previously published \[[@CR21]\]). The 4 di-2-ethylhexyl phthalate (DEHP) metabolites mono-2-ethylhexyl phthalate (MEHP), mono-2-ethyl-5-hydroxyhexyl phthalate (MEHHP), mono-2-ethyl-5-oxohexyl phthalate (MEOHP), mono-2-ethyl-5-carboxypentyl phthalate (MECPP) where measured and summed as ΣDEHP~m~ by addition of the molar sum of the four metabolites multiplied by the molecular weight of DEHP. Likewise, the 4 measured DiNP metabolites; mono-iso-nonyl phthalate (MiNP), mono-hydroxy-iso-nonyl phthalate (MHiNP), mono-oxo-iso-nonyl phthalate (MOiNP) and mono-carboxy-iso-octyl phthalate (MCiOP) were measured and summed as ΣDiNP~m~. We measured mono-iso-butyl phthalate (MiBP) and mono-*n*-butyl phthalate (MnBP) and combined them as MBP~i + n~, since the two metabolites have been shown to be highly correlated in the urine of the women of Odense Child Cohort \[[@CR22], [@CR23]\]. Finally, we measured mono-benzyl phthalate (MBzP) and monoethyl phthalate (MEP). Moderate to high correlation between all summed metabolites has been shown elsewhere \[[@CR23]\]. Preparation and storage of standard solutions and samples, instrumental LC-MS/MS analysis and general method validation has previously been described \[[@CR22]\].

To correct for urinary dilution, all samples with a phthalate metabolite concentration above the limit of detection (LOD) were osmolality adjusted. Osmolality was measured by the freezing point depression method \[[@CR24]\]. All measured urinary concentrations were subsequently normalized to the group median osmolality (0.63 x osm/kg) using the following equation: $$\documentclass[12pt]{minimal}
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This adjustment method was chosen because osmolality is less affected by other exogenous factors than other adjustment methods \[[@CR25]\]. Concentrations below the LOD were substituted by the metabolite specific LOD divided by the square root of 2.

Measurement of asthma and allergy {#Sec5}
---------------------------------

A Danish modified version of The International Study of Asthma and Allergies in Childhood (ISAAC) was administered at the 5 years' examination. Asthma outcomes were wheeze within the last 2 years, self-reported asthma, doctor diagnosed asthma and use of medicine to treat asthma/cold within the last 12 months. Self-reported asthma was defined as at least 3 episodes of wheeze (each lasting more than a day) within the last year. We used three different eczema outcomes; self-reported eczema, doctor-diagnosed eczema and use of prescribed medicine against atopic dermatitis or eczema of flexural folds. Self-reported eczema was defined as itchy symmetric eczema in the flexural folds behind the knees (which possibly came and disappeared again) within the last 6 months. Doctor diagnosed and use of prescribed medicine encountered all five life years, not just the last 6 months. Finally, we studied self-reported and doctor-diagnosed rhinitis defined as problems with recurrent sneezing and/or runny nose without having a cold or the flu and ever doctor diagnosed with hay fever. Due to a very low prevalence (1.3%) of doctor-diagnosed rhinitis, we did not study this outcome. Doctor diagnosed outcomes were all parental report of doctor's diagnosis.

Data analysis {#Sec6}
-------------

The children included in this study were first compared to the rest of the OCC population with regard to child- and upbringing characteristics using t-tests and chi2-tests for continuous and categorical variables, respectively. We then compared characteristics among participating children with and without asthma, eczema or rhinitis using the same tests. Median and 25--75 percentiles of phthalate metabolite concentrations were compared according to the mother-child and upbringing characteristics and differences in the distribution assessed by Mann Whitney and Kruskal-Wallis test. Furthermore, Kruskal Wallis test was used to test for differences in maternal phthalate metabolite concentrations between children with two, one and no allergic outcomes.

The distribution of phthalate metabolite concentrations was right-skewed and transformed by the natural logarithm (ln) to normalize distribution. The associations between ln transformed phthalate exposure and allergic outcomes were assessed using logistic regression. Phthalate metabolite concentrations were then back transformed to study the odds ratios (OR) for a doubling of phthalate exposure. We identified potential confounders using a directed acyclic graph based on existing literature (Fig. [1](#Fig1){ref-type="fig"}). Maternal age, educational level and parity were a priori expected to influence both exposure to phthalates and development of asthma, eczema and rhinitis and adjusted for in the final model to reduce model variance. Having a parent or sibling with allergy is a strong predictor for childhood allergy and was therefore included in the final model. In utero exposure to maternal smoking is a well-known risk factor for development of asthma, eczema and rhinitis, however, only 3% of mothers smoked during pregnancy, and this was therefore not included in the final model. To evaluate sex interactions, the interaction term of sex and phthalate metabolite were added in each model. However, the interaction was not significant, and was therefore removed from the final model. Fig. 1Directed acyclic graph (DAG) for evaluation of covariates in the logistic regression model. Legends: DAG for evaluation of covariates in the association between phthalates and asthma/allergy. Green nodes: Variables associated with maternal phthalate exposure. Blue nodes: Variables associated with asthma in the offspring. Red nodes: Variables associated with phthalates and asthma outcomes

Statistical analyses were conducted using STATA/IC 15.0, and *p*-values \< 0.05 were considered significant.

Results {#Sec7}
=======

Totally, 846 women had phthalate metabolites measured in their urine and 1316 parents of singleton children answered the questions about asthma at age 5 years. Finally, 552 mother-child pairs with phthalate metabolite measurements and information about asthma, eczema and rhinitis were available for inclusion. The participants did not differ from the rest of OCC, however, a smaller proportion of the included mothers smoked during pregnancy (data not shown). The included mothers were on average 31 years old when giving birth and 58% were nullipara (Table [2](#Tab2){ref-type="table"}).

We found that 22.3% of the children had experienced wheeze. Combining self-reported and doctor-diagnosed asthma, the prevalence of asthma was 7.4%. In total, 11.7% had self-reported eczema, whereas 9.2% reported rhinitis (Table [1](#Tab1){ref-type="table"}). Furthermore, 3.3% of the children had both rhinitis and one of the eczema outcomes and 1.7% had rhinitis and one asthma outcome. Only 4 children (0.8%) had an asthma outcome and an eczema outcome. Table 1Prevalence of allergic outcomesOutcomePrevalenceWheeze within the last 2 years22.3%Self-reported asthma4.7%Doctor-diagnosed asthma5.1%Use of medicine against asthma/cold13.8%Self-reported eczema11.7%Doctor-diagnosed eczema6.6%Medicine against eczema6.2%Self-reported rhinitis9.2%Rhinitis and eczema3.3%Rhinitis and asthma1.7%Asthma and eczema0.8%

Mothers of children with doctor diagnosed asthma had higher BMI and more often had pets. Preterm children wheezed more than children born at term, and children with a birth weight less than 2500 g more often had self-reported asthma compared to children with higher birth weight. Significantly more boys were doctor-diagnosed with asthma and had self-reported rhinitis. The prevalence of wheeze, self-reported asthma, doctor diagnosed asthma and self-reported rhinitis were higher between children with a family history of asthma compared to children without a family history of asthma. Maternal age and parity showed no significant association with asthma, rhinitis or eczema in our study (Table [2](#Tab2){ref-type="table"}). Table 2Characteristics (percent distribution) of the mother-child pairs according to allergic outcomesCharacteristicsn (%)\
552 (100)Wheeze within the last 2 years (*n* = 552)Self-reported asthma(*n* = 535)Doctor-diagnosed asthma (*n* = 530)Self-reported rhinitis (*n* = 532)Self-reported eczema (*n* = 487)Yes\
*n* = 123No\
*n* = 429Yes\
*n* = 25No\
*n* = 510Yes\
*n* = 27No\
*n* = 503Yes\
*n* = 49No\
*n* = 483Yes\
(57)No\
(430)Sex Boy278 (50.4)54.549.248.051.270.449.567.348.243.952.3 Girl274 (49.6)45.550.852.048.829.6\*50.5\*32.7\*51.8\*56.147.7Birth weight (grams)  \< 250013 (2.4)4.11.98.0\*2.2\*7.42.24.12.30.02.6 2500--4000435 (78.8)74.880.056.080.066.779.171.479.973.780.2  \> 4000104 (18.8)21.118.236.0\*17.8\*25.918.724.517.826.317.2Preterm birth (\<week 37) Yes24 (4.3)8.9\*3.0\*8.04.17.44.26.14.11.84.7 No528 (95.7)91.197.092.095.992.695.893.995.998.295.3Maternal age at delivery (years)  \< 2550 (9.1)13.07.98.09.211.18.96.19.515.89.3 25--29193 (35.0)35.834.740.034.729.635.236.734.626.336.3 30--34210 (38.0)33.339.432.038.437.038.436.737.936.837.4  ≥ 3599 (17.9)17.917.920.017.622.217.520.418.021.117.0BMI (kg/m^2^)  \< 2059 (10.7)10.6\*10.7\*0.011.211.1\*10.7\*12.210.114.010.9 20--25286 (51.8)42.354.548.052.422.253.738.852.638.653.7  ≥ 25207 (37.5)47.2\*34.7\*52.036.566.7\*35.6\*49.037.347.435.3Parity Nulliparous321 (58.2)65.056.264.057.551.957.761.257.863.258.4 Multiparous231 (41.8)35.043.836.042.548.142.338.842.236.841.6Smoking during pregnancy Yes16 (2.9)3.32.84.02.93.73.06.12.71.82.8 No536 (97.1)97.797.296.097.096.397.093.997.398.297.2Education level at pregnancy High school or less144 (26.3)38.3\*23.0\*20.0\*26.5\*33.325.734.725.733.326.8 High school + 1--4 years279 (51.0)41.753.636.051.548.151.051.050.050.951.4 High school + \> 4 years124 (22.7)20.0\*23.4\*44.0\*22.0\*18.523.314.324.315.821.8Breastfeeding (weeks)  \< 445 (9.4)9.19.213.6\*9.3\*9.19.213.3\*9.4\*9.810.2 4--1988 (18.4)27.317.736.416.827.317.733.316.817.618.7  \> 19345 (72.2)63.673.150.0\*73.9\*63.673.153.3\*73.8\*72.571.1Family history of asthma/allergy Yes309 (56.0)61.854.368.055.463.055.672.9\*54.9\*69.656.5 No243 (44.0)38.245.732.044.637.044.427.145.130.443.5Family history of asthma Yes115 (20.8)30.1\*18.2\*48.0\*18.6\*44.4\*18.9\*30.6\*18.8\*26.319.5 No437 (79.2)69.981.852.081.455.681.169.481.273.780.5Pets (inside and outside) Yes231 (42.4)50.040.252.0\*42.3\*59.3\*41.7\*63.843.437.042.6 No314 (57.6)50.059.848.057.740.758.336.256.663.057.4\**p*-value \< 0.05 when testing for significant differences in distribution between the group with an allergic outcome and the group without (using t-test for continuous and chi2-test for categorical variables)

To examine the levels of phthalate exposure, we measured the urinary phthalate concentrations and calculated the percentage of pregnant women who excreted levels above LOD. Phthalate metabolites were detectable in more than 90% of urine samples, except MBzP, which was detected in 68% of the samples (Table [3](#Tab3){ref-type="table"}). Mothers with high or low BMI excreted significantly higher concentrations of phthalate metabolites than normal weight women (Table [4](#Tab4){ref-type="table"}), otherwise no differences in maternal and child characteristics according to phthalate exposure were found. Table 3Urinary phthalate metabolite levels \[ng/mL\] measured in gestational week 28Diether phthalatePhthalate metaboliteLOD% \> LODMeanMinimumPercentileMaximum5th25th50th75th95thDEPMEP0.5399.8103.80.372.67.317.955.8351.55380.9DiBPMiBP1.1099.637.10.783.412.327.147.2104.1455.2DnBPMnBP1.4395.318.2\<LOD1.56.013.524.951.7184.3ΣMBP~(i + n)~55.3\<LOD4.919.141.574.7150.3516.1BBzPMBzP1.1467.94.63\<LOD2.55.815.771.2DEHPMEHP0.1490.21.7\<LOD0.461.12.25.536.8MEHHP0.9189.36.6\<LOD2.251.08.618.592.7MEOHP0.6791.55.4\<LOD\<LOD1.84.37.014.656.6MECPP0.5596.96.4\<LOD0.732.45.28.515.695.7ΣDEHP~m~26.5\<LOD1.59.421.434.669.0305.0DiNPMiNP0.6111.61.2\<LOD0.98135.5MHiNP0.2691.19.4\<LOD0.781.63.812.61433.4MOiNP0.2583.35.0\<LOD0.451.12.58.9690.4MCiOP0.11100.013.30.150.521.83.77.523.61438.4ΣDiNP~m~38.10.220.774.38.518.358.04956.8Abbreviations: *LOD* Limit of detection; *DEP* Diethyl phthalate; *DiBP* Diisobutyl phthalate; *DnBP* Di-n-butyl phthalate; *BBzP* Benzyl-butyl phthalate; *DEHP* Di-2-ethylhexyl phthalate; *DiNP* Diisononyl phthalate; *MEP* monoethyl phthalate; *MiBP* mono-isobutyl phthalate; *MnBP* mono-n-butyl phthalate; *MBzP* monobenzyl phthalate; *MEHP* mono-2-ethylhexyl phthalate; *MEHHP* mono-2-ethyl-5-hydroxyhexyl phthalate; *MEOHP* mono-2-ethyl-5-oxohexyl phthalate; *MECPP* mono-2-ethyl-5-carboxypentyl phthalate; *MiNP* mono-iso-nonyl phthalate; *MHiNP* mono-hydroxy-iso-nonyl phthalate; *MHiNP* mono-hydroxy-iso-nonyl phthalate; *MCiOP* mono-carboxy-iso-octyl phthalateTable 4Maternal median (25--75 percentile) osmolality adjusted urinary phthalate metabolite concentrations according to mother/child characteristicsCharacteristicsnMEP Median and 25-75th percentile (ng/ml)ΣMBP~i + n~ Median and 25-75th percentile\
(ng/ml)ΣDEHP~m~ Median and 25-75th percentile\
(ng/ml)ΣDiNP~m~ Median and 25-75th percentile\
(ng/ml)Sex Boy27822.2 (9.6--55.0)44.7 (27.1--71.4)22.0 (13.9--33.2)9.9 (5.8--19.7) Girl27419.6 (8.8--51.9)43.7 (26.3--69.2)21.8 (12.5--31.9)8.6 (5.1--15.8)Birth weight (grams)  \< 25001313.4 (6.8--20.9)37.7 (30.2--44.1)20.2 (15.8--22.3)7.2 (6.3--19.2) 2500--400043522.6 (9.8--51.9)45.2 (27.2--68.5)22.3 (13.5--33.0)9.0 (5.4--17.6)  ≥ 400010416.6 (8.0--65.6)42.5 (25.7--73.5)20.8 (12.3--30.1)10.8 (5.1--20.4)Preterm (\<week 37) Yes2417.8 (9.9--72.5)40.9 (28.8--70.1)20.8 (12.0--27.2)9.5 (5.7--20.7) No52821.4 (9.1--52.4)44.5 (26.6--70.0)22.0 (13.5--32.9)9.2 (5.4--18.3)Age at birth (year)  \< 255020.6 (8.9--37.7)44.3 (24.3--70.0)20.4 (14.7--33.0)9.3 (4.5--14.3) 25--2919319.8 (9.8--47.7)40.5 (26.1--66.2)21.2 (11.2--31.3)9.1 (5.1--19.3) 30--3421020.5 (8.9--55.0)45.0 (26.6--70.4)21.7 (14.2--32.5)9.3 (5.7--15.5)  ≥ 359925.2 (8.8--94.8)52.1 (35.7--75.1)24.0 (13.8--34.7)9.2 (6.4--19.7)BMI (kg/m^2^)  \< 205926.1 (10.6--55.0)49.1 (30.2--72.5)\*22.0 (15.0--29.3)\*7.4 (5.0--19.3)\* 20--2528619.5 (8.7--46.9)40.4 (22.4--63.0)20.4 (11.6--31.0)8.4 (5.0--14.8)  ≥ 2520725.4 (9.3--65.4)49.9 (30.5--75.4)\*24.0 (15.8--39.8)\*11.5 (6.6--20.5)\*Parity Nulliparous32120.9 (10.4--50.0)44.9 (27.0--69.4)21.8 (13.4--33.0)9.5 (5.4--19.2) Multiparous23121.4 (8.6--61.5)43.9 (26.5--70.1)22.0 (13.5--32.1)9.1 (5.2--15.8)Smoking Yes1626.2 (7.9--69.2)48.2 (25.8--76.4)24.1 (15.7--35.8)11.4 (4.7--20.4) No53621.0 (9.3--52.5)44.4 (26.7--69.7)21.9 (13.5--32.4)9.2 (5.4--18.3)Education level years Low14425.4 (10.6--65.6)48.5 (29.7--75.6)24.0 (13.5--39.0)10.2 (6.0--20.7) Intermediate27919.8 (8.8--55.8)43.0 (25.3--66.9)21.4 (13.5--31.0)9.0 (5.5--16.8) High12419.8 (9.1--39.6)45.8 (29.4--73.2)21.7 (12.9--31.6)8.5 (4.9--19.1)Breastfeeding  \< 4 weeks4517.0 (9.0--53.2)48.1 (36.1--75.2)24.8 (13.7--33.4)10.3 (7.0--21.2) 4--19 weeks8830.3 (14.2--91.4)49.9 (31.5--67.5)20.7 (15.2--32.8)12.8 (7.0--19.9)  \> 19 weeks41920.4 (9.3--49.2)43.3 (25.7--70.1)21.8 (13.1--32.1)8.6 (5.1--17.2)Family history of asthma/allergy Yes30919.5 (8.4--49.9)44.4 (27.2--68.5)21.6 (13.0--32.4)9.7 (5.3--20.3) No23923.2 (10.9--56.9)44.2 (26.0--71.1)22.3 (13.6--32.8)8.4 (5.4--14.8)Family history of asthma Yes11522.2 (8.1--54.1)41.2 (26.7--68.5)21.2 (13.0--32.4)9.0 (5.1--20.0) No43720.9 (10.2--52.5)45.2 (26.6--70.0)22.1 (13.5--32.5)9.2 (5.6--18.0)Abbreviations: *MEP* monoethyl phthalate; *ΣMBP*~*i + n*~ Monobutyl phthalate (i + n); *ΣDiNP*~*m*~ sum of Di-isonyl phthalate metabolites; *ΣDEHP*~*m*~ sum of Di-2-ethylhexyl phthalate metabolites\**p* \< 0.05 using Mann-Whitney test for difference between characteristics with 2 parameters, Kruskal-Wallis test for characteristics with more than 2 parameters

We then compared urinary phthalate concentrations in mothers of children with an allergic outcome to urinary concentrations in mothers of children without the outcome to detect differences. No significant differences in phthalate concentrations were found between children with and without asthma or eczema. Compared to children without rhinitis, children with self-reported rhinitis had been exposed to higher levels of DiNP, DEHP and DBP prenatally (only significant for DiNP). In contrast, mothers of children with asthma, rhinitis or eczema tended to have lower concentrations of MEP compared to mothers of non-allergic children (Table [5](#Tab5){ref-type="table"}). No differences in urinary phthalate concentrations between children with two allergic outcomes compared to children with one or no allergic outcomes were found (data not shown). Table 5Maternal median (25--75 percentile) urinary phthalate metabolite concentrations among offspring with or without allergic outcomesOutcomenMEP Median and 25--75 (ng/mL)ΣMBP~i + n~ Median and 25--75 (ng/mL)ΣDEHP~m~ Median and 25--75 (ng/mL)ΣDiNP~m~ Median and 25--75 (ng/mL)Wheeze within the last 2 years Yes12321.9 (9.6--56.9)39.7 (25.4--71.5)22.3 (12.2--33.8)9.4 (5.4--15.2) No42920.3 (9.0--51.9)45.2 (27.0--70.0)21.8 (13.7--32.3)9.2 (5.4--19.1)Self-reported asthma Yes2519.3 (12.7--67.2)41.9 (30.2--71.5)22.3 (13.9--33.8)10.7 (5.1--22.3) No51021.4 (9.1--52.5)44.5 (26.6--68.5)21.8 (13.5--32.4)9.2 (5.4--18.3)Doctor-diagnosed asthma Yes2716.4 (6.8--55.5)36.9 (18.3--74.2)23.1 (9.3--31.9)10.3 (4.0--22.3) No50321.8 (9.3--52.5)44.8 (27.1--68.5)21.9 (13.5--32.8)9.3 (5.4--18.4)Use of medicine for asthma/cold Yes7621.8 (10.3--66.3)38.7 (30.0--64.2)20.6 (9.6--32.6)8.6 (5.0--14.1) No47620.7 (9.1--52.0)45.2 (26.3--71.3)22.0 (13.5--32.4)9.4 (5.5--19.2)Self-reported eczema Yes5716.0 (8.9--35.4)43.5 (24.8--63.3)9.6 (5.1--20.7)21.5 (13.4--31.3) No43022.2 (10.2--55.5)44.5 (27.2--68.5)9.4 (5.5--19.0)22.2 (13.7--33.4)Doctor-diagnosed eczema Yes3214.4 (8.6--35.2)43.1 (19.9--60.4)9.6 (4.7--22.7)20.3 (12.1--31.8) No45522.2 (9.7--55.0)44.6 (27.2--69.2)9.4 (5.5--18.8)22.3 (13.8--33.2)Use of medicine against eczema Yes2418.2 (8.57--38.8)40.0 (23.6--62.5)11.0 (4.7--36.1)21.4 (13.4--32.7) No36623.7 (10.6--55.6)44.3 (27.9--68.5)9.7 (5.7--18.0)22.1 (14.0--33.4)Self-reported rhinitis Yes4917.8 (9.1--43.1)49.9 (32.0--81.9)25.2 (16.7--32.1)11.2^a^ (7.1--21.5) No48321.2 (8.9--55.0)44.1 (26.6--68.5)21.8 (13.5--33.0)9.0 (5.2--18.0)Abbreviations: *MEP* monoethyl phthalate; *ΣMBP*~*i + n*~ Monobutyl phthalate (i + n); *ΣDiNP*~*m*~ sum of Di-isonyl phthalate metabolites; *ΣDEHP*~*m*~ sum of Di-2-ethylhexyl phthalate metabolites^a^Significant difference in urinary phthalate concentrations between the group that answered "yes" and the group that answered "no" (using Mann-Whitney test)

Finally, we examined the association between urinary phthalate concentrations and ORs of allergic outcomes to study patterns or possibly significant associations in the study population. In adjusted logistic regression no clear associations were found, however, most ORs for asthma outcomes were below one. Maternal MEP concentration was associated with reduced odds of self-reported (OR = 0.81, 95% CI: 0.68,0.96) and doctor diagnosed eczema (OR = 0.82, 95% CI: 0.66,1.01) in the offspring. A doubling in ΣDiNP~m~ tended to increase the odds of using medication to treat eczema (OR = 1.24, 1.00,1.55). A doubling in ΣDiNP~m~ and ΣDEHP~m~ concentration increased the odds of having self-reported rhinitis, although not statistically significant (OR = 1.15, 95% CI: 0.97,1.36 and OR = 1.21, 95% CI: 0.93,1.58, respectively) (Table [6](#Tab6){ref-type="table"}). Table 6Adjusted odds ratios and 95% confidence interval for allergic outcomesOutcomeMEP OR and 95% CIΣMBP\
OR and 95% CIΣDEHP~m~\
OR and 95% CIΣDiNP~m~\
OR and 95% CIWheeze within the last 2 years1.00 (0.90,1.11)0.86 (0.72,1.04)0.91 (0.78,1.07)0.89 (0.78,1.02)Self-reported asthma1.02 (0.82,1.27)0.95 (0.67,1.36)0.98 (0.72,1.33)0.99 (0.77,1.28)Doctor-diagnosed asthma0.91 (0.73,1.12)0.80 (0.57,1.13)0.91 (0.68,1.21)0.94 (0.73,1.21)Use of medicine against asthma/cold0.99 (0.88,1.13)0.86 (0.70,1.08)0.87 (0.72,1.04)0.85 (0.72,1.00)Self-reported eczema0.81\*(0.68,0.96)0.90 (0.70,1.15)1.00 (0.80,1.26)1.03 (0.87,1.22)Doctor-diagnosed eczema0.82 (0.66,1.01)0.79 (0.55,1.10)0.94 (0.71,1.25)1.10 (0.90,1.36)Medicine against eczema0.88 (0.70,1.10)0.84 (0.58,1.23)1.02 (0.72,1.43)1.24 (1.00,1.55)Self-reported rhinitis0.91 (0.75,1.04)1.11 (0.84,1.46)1.21 (0.93,1.58)1.15 (0.97,1.36)Abbreviations: *OR* odds ratio; *95% CI* 95% confidence interval; *MEP* monoethyl phthalate; *ΣMBP* Monobutyl phthalate (i + n), *ΣDiNP*~*m*~ sum of Di-isonyl phthalate metabolites; *ΣDEHP*~*m*~ sum of Di-2-ethylhexyl phthalate metabolitesNote: ORs were adjusted for maternal age, maternal education, parity and family history of asthma/allergy. \* = *p* \< 0.05

Discussion {#Sec8}
==========

In this prospective cohort with lower phthalate exposure than similar previously reported cohorts \[[@CR7], [@CR8], [@CR12], [@CR18], [@CR19]\] we found no consistent associations between prenatal phthalate exposure and allergic outcomes in the offspring aged 5 years. Interestingly, prenatal DiNP and DEHP exposure tended to increase the risk of rhinitis, although not statistically significant. DEP exposure, measured as urinary MEP concentration, decreased the odds of eczema, while DiNP exposure tended to increase it. The reduction in eczema among DEP exposed may be explained by avoidance behavior, as mothers in families with a history of asthma/allergy had lower MEP-concentrations than mothers in families without asthma/allergy, indicating that they may use less creams and cosmetics containing DEP \[[@CR26]\]. In contrast, DiNP is difficult to avoid, as it is found in flooring, building material etc. \[[@CR4]\], and we found no differences in DiNP metabolite concentrations between mothers in predisposed and non-disposed families. However, mothers from families with a history of asthma/allergy did not have significantly lower MEP-concentrations compared to mothers from families without, so other parameters may play a role in the association.

Nine cohort studies \[[@CR7], [@CR8], [@CR10], [@CR14]--[@CR19]\] examined the association between prenatal phthalate exposure and wheeze and asthma. Some \[[@CR8], [@CR10], [@CR14], [@CR16], [@CR17], [@CR19]\] found association between maternal MnBP and DEHP metabolites and increased risk of wheeze or asthma in children aged 5--11 years. However, in one study \[[@CR7]\] a higher DEP exposure decreased the risk of wheeze in girls aged 6--7 years. One study \[[@CR15]\] found no associations between MEP, MnBP or MiBP and asthma. We did not find associations between phthalate exposure and asthma, probably because our mothers were less exposed and the diagnosis of asthma is difficult to verify before the children can collaborate \[[@CR2]\].

Ten cohort studies \[[@CR5], [@CR7], [@CR9], [@CR11]--[@CR16], [@CR19]\] examined the association between prenatal phthalate exposure and eczema. Two studies \[[@CR14], [@CR16]\] measured exposure in serum and detected an association between high concentration of MEHP and DiNP metabolites and decreased risk of eczema. Three studies \[[@CR11]--[@CR13]\] found that higher urinary concentrations of MBzP, MEP, MiBP and ΣDEHP~m~ was associated with increased odds of eczema in 2--5 years old children. One study \[[@CR5]\] suggested that higher urinary MBzP concentration increased the risk of eczema in 2-year old but not 5-year old children. Among Polish 2-year-olds, neither MEP, MBP, ΣDiNP~m~ nor ΣDEHP~m~ were associated with eczema \[[@CR9]\]. In our cohort DiNP exposure tended to increase the risk of using medicine against eczema, despite low exposure. Three studies \[[@CR7], [@CR15], [@CR19]\] examined MEP and MBP and eczema in 7-year-olds, and found no associations possibly because eczema often resolves at child age 6--7 years \[[@CR27]\].

One study \[[@CR15]\] found no association between maternal urinary concentrations of MEP, MnBP and MiBP and rhinitis in the offspring aged 3 years. To our knowledge, we are the first to report association between prenatal DiNP and DEHP exposure and rhinitis in 5-year-old children, but our findings need confirmation in larger cohorts of older children.

Phthalates are hypothesized to interfere with the immune and respiratory systems and promote the hyperresponsiveness seen in atopic diseases \[[@CR28]\]. In vitro, DEHP promotes Th2 polarization and enhances interleukin \[[@CR28], [@CR29]\], which causes IgE-production, smooth muscle contractility and mucus production \[[@CR30]\]. Furthermore, DEHP interacts with the nuclear hormone receptor family peroxisome proliferator-activated receptors, affecting alveolar maturation and reducing surfactant production, altering lung mechanics \[[@CR31]\]. Animal studies indicate that early life exposure to DEHP results in proinflammatory immune responses \[[@CR32]\].

Our study was large, population-based and prospective establishing temporal relationship between phthalate exposure and allergic disease. However, our children are most likely healthier than the general population as the prevalence of asthma was 7.4%, whereas it is 12% based on hospital contacts and disease-specific prescribed medications in a large study of Danish 5-year-old children \[[@CR1]\]. The participation rate in OCC was 43%, and participating mothers were older and more often non-smokers compared to not participating mothers \[[@CR20]\]. As young maternal age and smoking are well known risk factors for asthma this may explain the lower prevalence of asthma in our study \[[@CR33]\].

Information on allergy symptoms was obtained from questionnaires, which may be less accurate than the standard diagnostic criteria used by doctors. However, we used a modified version of the validated ISAAC questionnaire and misclassification of symptoms is unlikely to be related to phthalate exposure. Furthermore, more urine samples collected throughout pregnancy would have minimized the risk of misclassification due to temporal exposure variability. Given that the most vulnerable time for exposure to endocrine disrupting chemicals during pregnancy has not yet been determined, we may have misclassified exposures by measuring concentrations in the third trimester. Such nondifferental misclassifications can possibly underestimate outcomes related to phthalate exposure, which may explain our odds ratios close to 1. We detected a wide variation of phthalate concentrations in the urine samples (Table [3](#Tab3){ref-type="table"}). The wide variation is normal for human-biomonitoring studies of phthalates, and several longitudinal studies show that the intraindividual variation of the phthalates are most often lower than the interindividual variation \[[@CR6], [@CR34]\].

Although our cohort was relatively large, few children reported allergic symptoms, which made it difficult to adjust for more covariates without losing statistical power. Thus, we did not account for the contribution of childhood exposures, although studies have found association between postnatal phthalate exposure and development of asthma and allergy \[[@CR10], [@CR35]\]. Likewise, we did not adjust for exposure to other phthalates or other endocrine disrupting chemicals. Our correlation analysis showed moderate to high correlation between phthalate metabolites and distinguishing the effect of exposure to one phthalate from another phthalate is difficult. In addition, we tested many potential associations and our significant result may be due to chance.

Conclusions {#Sec9}
===========

In this low exposed prospective mother-child cohort we found no consistent association between maternal phthalate exposure and asthma and eczema in the offspring aged 5-years. Prenatal exposure to DiNP and DEHP was associated with rhinitis, although not significantly, possibly due to a relatively small number of 5-year-old children with rhinitis. Given the widespread use of phthalates, the possible association with rhinitis is of public health concern. It is therefore important to follow up the children with allergy testing, lung function assessment and phthalate exposure measurements, as the prevalence and diagnostic accuracy of allergic diseases will increase with age.
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